Results 11 to 20 of about 5,917,592 (236)
Colorectal Carcinoma with Extremely Low CA19-9 [PDF]
Gastroenterology Research and Practice, 2009 Aim. The aim of this study is to determine the significance of postoperative sequential measurements of serum CA19-9 in patients with extremely low serum level. Patients and Methods.
Yutaka J. Kawamura +6 more
doaj +5 more sources
Níveis séricos pré-operatórios dos marcadores CEA e CA19-9 e imunoexpressão tecidual do marcador CA19-9 no carcinoma colorretal: relação com os aspectos morfológicos da neoplasia [PDF]
Revista do Colégio Brasileiro de Cirurgiões, 2010 OBJETIVO: Comparar os níveis séricos de CA19-9 e CEA e a expressão tecidual do CA19-9 e relacioná-los com os aspectos morfológicos do carcinoma colorretal.
José Roberto Martins de Souza +5 more
doaj +4 more sources
Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis [PDF]
Translational Oncology, 2019 BACKGROUND: Presurgical carbohydrate antigen 19-9 (CA19-9) level predicts overall survival (OS) in resected pancreatic adenocarcinoma (PaC). The aim of this pooled analysis was to evaluate if presurgical CA19-9 level can also predict local control (LC ...
Gian Carlo Mattiucci +23 more
doaj +2 more sources
Combining CRP and CA19-9 in a novel prognostic score in pancreatic ductal adenocarcinoma [PDF]
Scientific Reports, 2021 Inflammation promotes tumor progression, induces invasion and metastatic spread. This retrospective study explored CRP, CA19-9, and routine laboratory values as preoperative prognostic factors in pancreatic cancer patients.
Anna M. Nurmi +4 more
doaj +2 more sources
Serum CA19-9 determination in the management of pancreatic cancer
, 1996 Background/Aim: CA19-9 is a tumor marker present in the serum of 70-90% of patients with pancreatic carcinoma. In order to investigate the value of CA19-9 determination in the clinical management of patients with pancreatic cancer, we performed a ...
Van Den Bosch, R. P. +3 more
core +10 more sources
Abdominal Pain and Increased CA19-9 [PDF]
Clinical Chemistry, 2013 A 32-year-old man with an unremarkable medical history presented to the ambulatory clinic with complaints of nonlocalized abdominal pain. The results of a physical examination were unremarkable. The results obtained from liver, pancreatic, and renal testing were within the reference intervals, and the results of both a fecal occult blood test and an ...
Graziani G. +4 more
openaire +2 more sources
CA19-9 as a therapeutic target in pancreatitis [PDF]
Annals of Translational Medicine, 2019 The glycan carbohydrate antigen 19-9 (CA19-9) is one of the most important and widely used biomarkers for pancreatic cancer. In 1979, Koprowski et al. first described CA 19-9 as a tumor antigen recognized by the monoclonal antibody NS19-9 (1).
Shingo, Kato, Kazufumi, Honda
openaire +2 more sources
Frontiers in Oncology, 2020 Recently we showed that delta radiomics features (DRF) from daily CT-guided chemoradiation therapy (CRT) is associated with early prediction of treatment response for pancreatic cancer.
Haidy Nasief +6 more
doaj +1 more source
CA19-9 for detecting recurrence of pancreatic cancer [PDF]
Scientific Reports, 2020 AbstractCA19-9 values are regularly measured in patients with pancreatic cancer. Certainly, its potential as a biomarker has been compromised by false negative results in CA19-9 negative patients and false positive results in benign pancreatico-biliary diseases. For detection of PDAC recurrence, however, CA19-9 might play an important role.
Azadeh Azizian +9 more
openaire +3 more sources
Frontiers in Oncology, 2022 BackgroundPancreatic cancer mortality is growing every year, and radical resection is the most essential therapy strategy. It is critical to evaluate the long-term prognosis of individuals receiving radical surgery.
Zuowei Wu +7 more
doaj +1 more source